In line with this notion, it is generally appealing to implement predisposing or causative genetic lesions as diagnostic targets for the measurement of MRD as established for various MLL-gene fusions in infant ALL or, as recently published, for ETV6-RUNX1 breakpoints43–45. This evidence concerns the gene RUNX1 and acute lymphoblastic leukemia.